Harvard Business Review September 4, 2024
David Blumenthal, Bakul Patel

Summary: A challenge confronting the Food and Drug Administration — and other regulators around the world — is how to regulate generative AI. The approach it uses for new drugs and devices isn’t appropriate. Instead, the FDA should be conceiving of LLMs as novel forms of intelligence. It should employ similar approaches to those it applies to clinicians.

Generative AI has arrived in medicine. Normally, when a new device or drug enters the U.S. market, the Food and Drug Administration (FDA) reviews it for safety...

Today's Sponsors

Venturous
Got healthcare questions? Just ask Transcarent

Today's Sponsor

Venturous

 
Topics: AI (Artificial Intelligence), Govt Agencies, Regulations, Technology
Is Apple Intelligence the new Apple Maps?
Headways and hurdles: How AI is shaping the future of medicine
Overhyped: Manus From Monica — AI Made In China
Silicon Valley Startup Inception Labs Creates Faster LLM
AI model uses ECGs to detect females at high risk of heart disease

Share This Article